Wei Yue, Ph.D.

---

Summary

My research program focuses on studying novel mechanisms involved in regulation of OATP1B1 and OATP1B3 transport function. The long-term goal of my laboratory is to establish a mechanistic model to predict OATP-mediated drug-drug interactions, toxicities and inter-individual variability in drug response. Multi-disciplinary approaches are utilized including: 1) Sandwich-cultured primary human hepatocytes model; 2) Physiologically based pharmacokinetic (PBPK) modeling approach to assess clinically relevant DDIs; 3) Pharmacogenomics studies of drug transport proteins; 4) Post-translational regulation of OATP transporters; 5) Confocal microscopy to study trafficking of the transport proteins.

Academic Awards

---

Publications & Presentations

16. Kayesh R, Farasyn T, Crowe A, Liu Q, Pahwa S, Alam K, Ding K, Neuhoff S, Hatley O, Yue W. Assessing OATP1B1- and OATP1B3-mediated drug-drug interaction potential of vemurafenib using static and physiologically based pharmacokinetic models. PharmSci 360-AAPS Annual Meeting. 2019

17. Wang L, Yue W, Hu M. Cellular uptake kinetic studies of Wogonoside, Luteolin 3’-glucuronide and apigenin 7-glucuronide in OATP1B1, 1B3 and 2B1 overexpressed HEK-293 cell lines. PharmSci 360-AAPS Annual Meeting. 2019

18. Crowe A, Miller J, Yue W. Genotyping of the OATP1B1 c. 521 T>C polymorphism from the Formalin-Fixed Paraffin-Embedded (FFPE) tissue specimens: an optimized protocol. Bio-Protocol. 2019; 9

19. Crowe A, Zheng W, Miller J, Pahwa S, Alam K, Fung K, Rubin E, Yin F, Ding K, Yue W. Characterization of plasma membrane localization and phosphorylation status of organic anion transporting polypeptide (OATP) 1B1 c.521 T>C polymorphism. Pharmaceutical Research. In Press; 36 : 101

20. Farasyn T, Crowe A, Hatley O, Neuhoff S, Alam K, Kanyod J, Lam T, Ding K, Yue W. Preincubation with everolimus and sirolimus reduces organic anion transporting polypeptide (OATP)1B1- and 1B3-mediated transport independently of mTOR kinase inhibition: implication in assessing OATP1B1- and OATP1B3-mediated drug-drug interactions. Journal of Pharmaceutical Sciences. 2019; 108 : 3443

Grants

6. Elucidating novel mechanism underlying OATP1B1/1B3-mediated drug-drug interactions . Non-federal. Start Date: 2019. End Date: 2020.

7. Characterize ADME of compound X. Non-federal. Start Date: 2019. End Date: 2020.

8. Post-translational regulation of hepatic transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3 by immunosuppressant cyclosporine A: Implication in Transporter-Mediated Drug-Drug Interactions. Misc Non-Federal. Start Date: 2018. End Date: 2019.

9. Post-translational regulation of transporters organic anion transporting polypeptides (OATP) 1B1 and 1B3 by immunosuppressant cyclosporine A: Implication in Transporter-Mediated Drug-Drug Interactions . Misc Non-Federal. Start Date: 2017. End Date: 2018.

10. Administrative amendment of adding human subject research component to current funded R01. NIH. Start Date: 2017. End Date: 2017.

Awards and Honors

6. OUHSC. Tenure . Date: 2020.


7. Shandong University, China. Sunshine scholarship. Date: 1996.


8. Shandong Agriculture University. Excellent Student Leader . Date: 1994.


9. Shandong Province, China. Excellent Student Leader . Date: 1993.


10. Chinese Ministry of Education. Outstanding Student of China . Date: 1993.

Education

1. Degree: Postdoctoral training. Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. Date: 2008.


2. Degree: Postdoctoral Training. Lineberger Comprehensive Cancer Center, Univeristy of North Carolina at Chapel Hill. Date: 2007.


3. Degree: Ph D. Peking Union Medical College and Shandong University, China. Date: 2001.


4. Degree: MS. Shandong University, China. Date: 1998.


5. Degree: BS. Shandong Agricultural University, China. Date: 1995.

Administrative Assignments

no results